Trial Registered

Beijing QL adds cardiac-safety trial for obesity candidate zovaglutide

The Phase 1 QTc study in healthy adults is a routine regulatory checkbox that will feed the safety package behind zovaglutide's Phase 3 obesity program.

By AppliedXLJuly 13, 2026Trial NCT07697846

Executive Summary

Beijing QL Biopharmaceutical registered a new Phase 1 study to test whether its GLP-1 receptor agonist zovaglutide prolongs the QTc interval, a cardiac-safety measure regulators use to screen for arrhythmia risk.
The study sits alongside the company's Phase 3 obesity trial for the same drug, positioning this safety data to support that later-stage program rather than to test efficacy on its own.
The exclusion criteria and exposure-response modeling built into the design point to a rigorous cardiac-safety assessment consistent with what regulators expect before a GLP-1R agonist advances toward approval.
Zovaglutide enters a GLP-1R agonist field with several Phase 3 programs already underway from larger sponsors, so this trial's main value is de-risking the mechanism for Beijing QL's own pipeline rather than differentiating it from rivals.

The new trial

The study, filed under NCT07697846, will enroll 40 healthy adults in China to assess the change in placebo- and baseline-corrected QTc interval, its registered primary endpoint, through linear mixed-effect exposure-response modeling of ZT002 (zovaglutide) plasma concentrations. The trial has not yet started recruiting, with a start date of July 18, 2026 and a primary completion date of January 13, 2027. Secondary endpoints track heart rate, PR interval, QRS duration, T-wave and U-wave morphology, alongside standard pharmacokinetic parameters and body-weight-related measures through day 141. NCT07697846

What the design tests

The eligibility criteria exclude participants with QTcF at or above 450 ms, PR interval above 220 ms, QRS duration above 110 ms, or personal or family history of long QT syndrome or sudden cardiac death. That screening, paired with exposure-response modeling of drug concentration against the corrected QT interval, is the design used for a thorough cardiac-safety assessment rather than an efficacy study. A single-arm, healthy-volunteer Phase 1 design of this kind is built to generate a decision-grade safety signal on cardiac conduction, not a broader clinical read. NCT07697846

Where it sits in the pipeline

Zovaglutide is also being tested in a Phase 3 obesity trial (NCT07230119, HORIZON-1), targeting 744 participants with a primary completion date of May 29, 2027, and in a Phase 1 renal-impairment study (NCT07443059) that is currently recruiting. The QTc study supplies a piece of the safety data package that typically accompanies a GLP-1R agonist through later-stage development and eventual regulatory review, rather than standing as an independent readout of the drug's obesity efficacy. NCT07697846

The competitive field

GLP-1 receptor agonists and related incretin mechanisms account for a large share of active obesity and metabolic-disease trials, with Eli Lilly, Novo Nordisk, Roche, Pfizer, and several Chinese sponsors including Gan & Lee Pharmaceuticals running Phase 3 programs on the same target. Zovaglutide has no eligible direct comparator trial identified in that field, since none shares both its target and a matched trial design for head-to-head comparison. Beijing QL's own trial record shows six completed studies with no terminations across its Incretin-receptor programs, a track record on the smaller side that nonetheless shows consistent completion.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.